Welcome to our dedicated page for Chemomab Therapeutics Ltd. SEC filings (Ticker: CMMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Chemomab Therapeutics Ltd. filings document a foreign private issuer focused on clinical-stage biotechnology and traded through American Depositary Shares. Its Form 6-K reports furnish operating updates, quarterly and year-end financial results, unaudited consolidated financial statements, management discussion and analysis, and press releases on the nebokitug program in primary sclerosing cholangitis.
The filing record also covers ADS and capital-structure matters, including at-the-market offering arrangements, ADS ratio-adjustment disclosures, shelf registration and equity incentive registration references, and annual general meeting materials. Proxy-related filings describe shareholder voting procedures for ADS holders, director elections, compensation policy approval, authorized share capital amendments, auditor re-appointment, quorum matters, and governance under Israeli company law.
Chemomab Therapeutics Ltd. director Neil Harris Cohen filed a Form 3 disclosing his initial beneficial ownership in the company’s American Depositary Shares. He directly holds 35,304 American Depositary Shares as of the reporting date.
He also holds several stock options to buy additional American Depositary Shares at exercise prices ranging from $2.14 to $109.04 per share, with expirations between 2030 and 2036. Footnotes state these options were granted between July 16, 2020 and March 16, 2025 and are all fully vested and exercisable as of the report date, showing his existing equity-based compensation position rather than new market transactions.
Chemomab Therapeutics Ltd. director Alan Charles Moses filed an initial Form 3 showing his holdings of stock options over American Depositary Shares. The filing lists several option grants at exercise prices ranging from $2.14 to $109.04 per ADS. According to the notes, these options are fully vested and exercisable as of the report date.
Chemomab Therapeutics Ltd. Chief Financial Officer Fatal Sigal filed an initial ownership report showing current holdings in American Depositary Shares (ADSs), stock options, and restricted share units. The filing lists three option grants over ADSs with exercise prices of $39.31, $8.44, and $6.80 per ADS, expiring between November 2031 and June 2033, along with multiple ADS and RSU positions that vest in stages through 2029.
Chemomab Therapeutics Ltd. Chief Development Officer John Lawler filed an initial Form 3 reporting his existing equity interests in the company. This filing does not show any new purchases or sales, only current holdings.
Lawler holds stock options over 12,500, 10,864 and 7,500 American Depositary Shares with exercise prices of $20.52, $5.68 and $2.20 per ADS, expiring in 2032, 2033 and 2034, respectively. Some of these options are already fully vested, while others vest in quarterly installments.
He also reports direct holdings of American Depositary Shares, including awards of RSUs granted in October 2024 and April 2025 that vest 25% on the first anniversary of grant and then in 12 quarterly installments of 6.25% until October 1, 2028 and April 10, 2029.
Chemomab Therapeutics Ltd. director Jill M. Quigley filed an initial statement of beneficial ownership that lists her stock option holdings over the company’s American Depositary Shares. The filing shows four option grants with different exercise prices and long-dated expirations.
Quigley holds options over 3,410 ADS at an exercise price of $13.00 per share expiring on June 16, 2032; 1,714 ADS at $6.80 expiring on June 14, 2033; 2,533 ADS at $4.00 expiring on June 16, 2034; and 3,959 ADS at $5.24 expiring on June 16, 2035. Footnotes state that options granted on June 16, 2022, June 14, 2023, and June 16, 2024 are fully vested and exercisable as of the report date.
Chemomab Therapeutics Ltd. director Claude Nicaise reported his initial holdings of stock options to buy the company’s American Depositary Shares. The filing lists six option awards with exercise prices ranging from $2.14 to $109.04 per share and expiration dates between 2031 and 2036. Footnotes state that options granted on April 19, 2021, March 7, 2022, March 21, 2023, March 18, 2024 and March 16, 2025 are fully vested and exercisable as of the report date. The Form 3 records ownership only and does not show any recent purchases or sales.
Chemomab Therapeutics, a clinical-stage Israeli biopharma company, filed its annual report outlining its business, key risks and financial position. The company focuses on nebokitug (CM-101), a monoclonal antibody targeting CCL24 for fibrotic and inflammatory diseases such as primary sclerosing cholangitis and systemic sclerosis.
As of December 31, 2025, Chemomab had 575,381,320 ordinary shares outstanding, equal to 7,192,276 ADSs. Cash, cash equivalents and deposits totaled $10.4 million, against an accumulated deficit of $111.6 million. Management expects existing cash to fund operations only through the end of the first quarter of 2027 and explicitly states substantial doubt about the company’s ability to continue as a going concern without raising additional capital.
The filing stresses that Chemomab has no approved products and is highly dependent on the success of nebokitug, which remains in clinical development and will require significant additional trials, regulatory approvals and funding. Extensive risk disclosures highlight clinical, regulatory, manufacturing, intellectual property, cybersecurity, geopolitical and Nasdaq listing risks, as well as potential dilution from future equity financings and volatility in the ADS trading price.
Chemomab Therapeutics Ltd. has called its Annual General Meeting for April 28, 2026 in Ramat Gan, Israel, asking shareholders to vote on four key proposals. Shareholders will be asked to re-elect two Class II directors, Neil Cohen and Claude Nicaise, for terms running to the 2029 meeting.
Investors are also being asked to approve a refreshed compensation policy for executive officers and directors, which the company describes as largely similar to the existing policy with some updates. Another proposal would increase authorized share capital by 8,000,000,000 ordinary shares, bringing total authorization to 12,650,000,000 ordinary shares of no par value.
The final proposal seeks to reappoint Somekh Chaikin, a member firm of KPMG International, as independent auditors for the year ending December 31, 2026, with the board authorized to set fees. As of March 19, 2026, 7,200,387 American Depositary Shares were outstanding, each representing 80 ordinary shares and carrying one vote at the meeting.
Chemomab Therapeutics reported 2025 results showing progress on both its nebokitug program and its finances. Following strong Phase 2 SPRING data in primary sclerosing cholangitis (PSC), the company completed a successful FDA End-of-Phase 2 meeting and reached alignment on a single Phase 3 registration trial design using a clinical event-driven composite endpoint.
For the year ended December 31, 2025, Chemomab recorded a net loss of 8,995 thousand, an improvement from 13,945 thousand in 2024, as total operating expenses declined to 9,567 thousand from 14,739 thousand. Research and development expenses fell to 5,833 thousand and general and administrative expenses were 3,734 thousand. As of December 31, 2025, total assets were 13,812 thousand and shareholders’ equity was 12,334 thousand, supported by 575,381,320 Ordinary Shares outstanding.
Peter Thiel and Rivendell Investments 2017-9 LLC report a 4.6% passive stake in Chemomab Therapeutics Ltd. on Schedule 13G/A. They beneficially own 22,631,200 ordinary shares as of December 31, 2025, based on 492,409,320 shares outstanding as of September 30, 2025.
The position is held through American Depositary Shares and a warrant: 22,170,160 ordinary shares represented by 277,127 ADSs and 461,040 ordinary shares represented by 5,763 ADSs issuable upon warrant exercise. Each ADS represents 80 ordinary shares. The filers state the securities are not held to change or influence control.